Efficacy studies of Sclerotium rolfsii lectin on breast cancer using NOD SCID mouse model

Abstract

Expression of altered glycans such as TF, Tn, and sTn antigens has been observed in a number of carcinomas which are targeted in cancer therapy. Sclerotium rolfsii lectin (SRL) is known to recognize TF and its substituted forms. Clinical potential of SRL has been demonstrated by studying its interaction with different types of cancer cells. Here we report, in vitro studies of SRL on breast cancer MDA-MB-468 cells and in vivo studies with MCF-7 xenografts. In vitro growth inhibitory studies of SRL on metastatic triple negative breast cancer MDA-MB-468 cells were performed by MTT assay, flow cytometry, adhesion, and CAM assay. In vivo efficacy studies of SRL were performed using NOD SCID mice bearing MCF-7 xenografts. SRL has strong binding to MDA-MB-468 cells with MFI of 85.5 and has growth inhibitory effect with IC of 32 μg/ml at 48 hr. SRL has antiangiogenesis effect and also anti adhesive effect with fibronectin and collagen at 20 μg/ml by 36% and 42%, respectively. In vivo efficacy studies of SRL on NOD SCID mice bearing MCF-7 xenogratfs revealed 61.77% and 75.71% tumor regressing effect, respectively, at 20 and 30 mg/kg body weight without any toxicity. All these results substantiate clinical potential of SRL on breast cancer.

Trichosanthes dioica seed lectin inhibits Ehrlich ascites carcinoma cells growth in vivo in mice by inducing G 0 /G 1 cell cycle arrest

“…With increased concentration or exposure time, the antiproliferative activity is also increased (De Mejía & Prisecaru, 2005;Valadez-Vega et al, 2011). Several plant lectins retained cytotoxic effects against different cancer cell lines and caused cell death in vitro and in vivo (Anupama et al, 2017;Hasan et al, 2019;Hegde et al, 2018;Nascimento et al, 2019) without causing toxicity in normal cells (Fik et al, 2001). EAC cells are considered as a suitable model cell line for anticancer drug test because of the absence of H-2 histocompatibility antigens (Chen & Watkins, 1970), which may be the ground behind their accelerated proliferation and made them studying in almost every mouse host.…”

Lectins as a promising therapeutic agent for breast cancer: A review

“…For the betterment of cancer patients, research has been going on to find an alternative mode of action for treatment than chemotherapy and chemoprevention. In this regard, SRL has shown many properties that can be useful in combating tumor cells [142]. In many cancer therapies, we observe that along with tumor cell destruction, some normal cells are also affected which might be detrimental to the patients body.…”

“…On a mice model that had MCF-7xenografts, SRL efficacy was observed. It was found that SRL was inhibiting tumor proliferation [142]. (4) Helix pomatia: Helix pomatia agglutinin (HPA) obtained from the Roman snails is part of the carbohydrate-binding protein family.…”

Recent advances in the use of legume lectins for the diagnosis and treatment of breast cancer

“…The current literature reports on the application of lectins of several origins in cancer models, namely of animal lectins [30][31][32] , microorganisms lectins [33,34], and, most of all, plant lectins. This review aims to highlight these studies with particular focus on plant lectins applied on the recognition of BCa glycans, as well as their cytotoxic/antiproliferative effects.…”